Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Invested Capital (2022 - 2025)

Historic Return on Invested Capital for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.63%.

  • Zentalis Pharmaceuticals' Return on Invested Capital fell 600.0% to 0.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.49% for FY2024, which is 1900.0% up from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Return on Invested Capital is 0.63%, which was down 600.0% from 0.64% recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Return on Invested Capital high stood at 0.53% for Q2 2024, and its period low was 0.67% during Q1 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Return on Invested Capital averaged around 0.59%, with its median value being 0.57% (2023).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Return on Invested Capital crashed by -1200bps in 2023 and then skyrocketed by 1000bps in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Return on Invested Capital stood at 0.53% in 2022, then fell by -24bps to 0.65% in 2023, then grew by 15bps to 0.55% in 2024, then decreased by -13bps to 0.63% in 2025.
  • Its last three reported values are 0.63% in Q3 2025, 0.64% for Q2 2025, and 0.67% during Q1 2025.